Duopharma Biotech Bhd

KLSE:DPHARMA

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is DPHARMA's stock price target?

Price Target

1.5 MYR

According to Wall Street analysts, the average 1-year price target for DPHARMA is 1.5 MYR with a low forecast of 1.42 MYR and a high forecast of 1.6 MYR.

What is Duopharma Biotech Bhd's Revenue forecast?

Projected CAGR

9%

For the last 8 years the compound annual growth rate for Duopharma Biotech Bhd's revenue is 13%. The projected CAGR for the next 3 years is 9%.

What is Duopharma Biotech Bhd's Operating Income forecast?

Projected CAGR

23%

For the last 8 years the compound annual growth rate for Duopharma Biotech Bhd's operating income is 6%. The projected CAGR for the next 3 years is 23%.

What is Duopharma Biotech Bhd's Net Income forecast?

Projected CAGR

27%

For the last 8 years the compound annual growth rate for Duopharma Biotech Bhd's net income is 5%. The projected CAGR for the next 3 years is 27%.